- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.03. | Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025 | 1 | Cision News | ||
| 19.03. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 19.03.2025 | 109 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 19.03.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 19.03.2025ISIN NameDK0061295797 CURASIGHT A/S DK -... ► Artikel lesen | |
| 27.02. | CURASIGHT: Year-end report Q4 2024 | 2 | Cision News | ||
| 05.02. | Curasight announces an updated financial calendar 2025 | 2 | Cision News | ||
| 31.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 31.01.2025 | 695 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.01.2025
Aktien
1 CA6699882065 Nu E Power Corp.
2... ► Artikel lesen | |
| 10.12.24 | Participation in warrant exercise by Curasight management | 2 | Cision News | ||
| 10.12.24 | Curasight A/S announces outcome of warrant exercise | 2 | Cision News | ||
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 02.12.24 | CURASIGHT: SEB maintain valuation range midpoint at DKK 54 per share | 5 | Cision News | ||
| 02.12.24 | CURASIGHT: The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024 | 3 | Cision News | ||
| 28.11.24 | Spotlight Stock Market: Market Notice 251/24- Last day of trading in Curasight A/S's subscription option CURAS TO 2 | 1 | Cision News | ||
| 26.11.24 | Curasight CEO reflects on a Q3 with strong progress | 1 | Cision News | ||
| 22.11.24 | Curasight and Curium sign global radioisotope supply agreement for uTREAT[®] | 1 | Cision News | ||
| 21.11.24 | CURASIGHT: The exercise period for warrants of series TO2 commences today | 1 | Cision News | ||
| 21.11.24 | CURASIGHT: Interim report Q3 2024 | 4 | Cision News | ||
| 20.11.24 | CURASIGHT: The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share | 5 | Cision News | ||
| 15.11.24 | Curasight announces brain cancer as initial target for uTREAT | 1 | Cision News | ||
| 14.11.24 | Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference | 2 | Cision News | ||
| 13.11.24 | Curasight announces international patent application for uTREAT® to broaden IP protection | 1 | Cision News | ||
| 11.11.24 | Curasight will present at the BioStock Life Science Summit, November 21 | 1 | Cision News | ||
| 11.11.24 | Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025 | 1 | Cision News |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 46,220 | 0,00 % | Tempus AI, Inc. (NASDAQ:TEM) Sees Significant Increase in Short Interest | ||
| EDGEWISE THERAPEUTICS | 13,600 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| QIAGEN | 36,500 | +0,83 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 43,110 | -7,33 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,425 | 0,00 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard | ||
| AVIDITY BIOSCIENCES | 28,120 | -5,54 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 16,180 | -2,53 % | Arcutis Biotherapeutics, Inc.: Arcutis and Padagis Agree to Stay Patent Lawsuit | WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| OSR HOLDINGS | 2,430 | 0,00 % | OSR Holdings Inc.: OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate ... | SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,800 | 0,00 % | Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March | ||
| CG ONCOLOGY | 18,750 | -16,41 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,470 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 13,415 | +2,80 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen | |
| IMMUNOVANT | 15,770 | 0,00 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | 0,00 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| BIONTECH | 82,70 | -1,14 % | BioNTech-Aktie: Das tragische Ende! | News von Trading-Treff.de Für die BioNTech sieht es nach einem tragischen Ende des Aufwärtsmarsches aus. Die Mainzer haben auch am Donnerstag einen Abschlag in Höhe von mehr als -1,9 % hinnehmen müssen.... ► Artikel lesen |
CURASIGHT A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.
